169 related articles for article (PubMed ID: 34292664)
1. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
Galluppi GR; Polhamus DG; Fisher JM; Hopkins SC; Koblan KS
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1245-1254. PubMed ID: 34292664
[TBL] [Abstract][Full Text] [Related]
2. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
3. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
[TBL] [Abstract][Full Text] [Related]
4. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
5. Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.
Chen YL; Tsukada H; Milanovic S; Shi L; Li Y; Mao Y; Koblan KS; Galluppi GR
Neurol Ther; 2023 Jun; 12(3):815-832. PubMed ID: 36932300
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
Szabo ST; Hopkins SC; Lew R; Loebel A; Roth T; Koblan KS
Sleep Med; 2023 Jul; 107():202-211. PubMed ID: 37209427
[TBL] [Abstract][Full Text] [Related]
7. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
8. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
[TBL] [Abstract][Full Text] [Related]
9. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
Xiao G; Tsukada H; Chen YL; Shi L; Hopkins SC; Galluppi GR
Pharmacol Res Perspect; 2024 Apr; 12(2):e1191. PubMed ID: 38527949
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
12. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
13. A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study.
Chen YL; Shi Y; LaFayette A; Shi L; Koblan KS; Galluppi GR
J Pharm Biomed Anal; 2022 Jan; 207():114404. PubMed ID: 34700199
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
Feemster JC; Westerland SM; Gossard TR; Steele TA; Timm PC; Jagielski JT; Strainis E; McCarter SJ; Hopkins SC; Koblan KS; St Louis EK
Sleep Med; 2023 Jan; 101():578-586. PubMed ID: 36584503
[TBL] [Abstract][Full Text] [Related]
15. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
16. A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
Tsukada H; Milanovic SM; Darpo B; Xue H; Xiong K; Tripp E; Lennek L; Worden M; Hopkins SC; Galluppi GR
Clin Transl Sci; 2023 Jun; 16(6):1063-1074. PubMed ID: 36949248
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.
Correll CU; Koblan KS; Hopkins SC; Li Y; Heather Dworak ; Goldman R; Loebel A
NPJ Schizophr; 2021 Dec; 7(1):63. PubMed ID: 34887427
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
[TBL] [Abstract][Full Text] [Related]
19. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
[TBL] [Abstract][Full Text] [Related]
20. Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Perini F; Nazimek JM; Mckie S; Capitão LP; Scaife J; Pal D; Browning M; Dawson GR; Nishikawa H; Campbell U; Hopkins SC; Loebel A; Elliott R; Harmer CJ; Deakin B; Koblan KS
Schizophrenia (Heidelb); 2023 Aug; 9(1):49. PubMed ID: 37550314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
